AR014000A1 - METHOD FOR USING CYCLOOXYGENASE-2 INHIBITORS IN THE MAINTENANCE OF FETAL DUCTUS ATERIOSUS DURING TREATMENT AND PREVENTION OF WORK PREMATURE WORK - Google Patents

METHOD FOR USING CYCLOOXYGENASE-2 INHIBITORS IN THE MAINTENANCE OF FETAL DUCTUS ATERIOSUS DURING TREATMENT AND PREVENTION OF WORK PREMATURE WORK

Info

Publication number
AR014000A1
AR014000A1 ARP980105483A ARP980105483A AR014000A1 AR 014000 A1 AR014000 A1 AR 014000A1 AR P980105483 A ARP980105483 A AR P980105483A AR P980105483 A ARP980105483 A AR P980105483A AR 014000 A1 AR014000 A1 AR 014000A1
Authority
AR
Argentina
Prior art keywords
alkyl
work
arylamine
cyclooxygenase
inhibitors
Prior art date
Application number
ARP980105483A
Other languages
Spanish (es)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR014000A1 publication Critical patent/AR014000A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invencion se relaciona con el uso de inhibidores de la ciclooxigenasa -2, o con derivados de los mismos, en la prevencion y el tratamiento deltrabajo de parto prematuro. En particular, la invencion describe un método para prevenir y tratar un parto prematuro en un sujeto, comprendiendo dicho métodoel tratamiento del sujeto con una cantidad terapéuticamente efectiva de un compuesto de formula (I) donde A es un sustituyente en anillo de 5 o 6 miembrosseleccionado entre anillos heterocíclicos y carbocíclicos insaturados o parcialmente insaturados, donde R1 es por lo menos un sustituyenteseleccionado entre heterociclos, cicloalquilo, cicloalquenilo y arilo, donde R1 está sustituido optativamente en una posicion sustituible, con uno o másradicales seleccionados entre alquilo, haloalquilo, ciano, carboxilo, alcoxicarbonilo, hidroxilo, hidroxialquilo, haloalcoxi, amina, alquilamina,arilamina, nitro, alcoxialquilo, alquilsulfinilo, halo, alcoxi y alquiltio, donde R3 se selecciona entre alquilo y amina y R3 es un radical seleccionadoentre halo, alquilo, alquenilo, alquinilo, oxo, ciano, carboxilo, cianoalquilo, heterocicloxi, alquiloxi, alquiltio, alquilcarbonilo, cicloalquilo arilo,haloalquilo, heterociclo, cicloalquenilo, aralquilo, heterocicloalquilo, acilo alquiltioalquilo, hidroxialquilo, alcoxicarbonilo, arilcarbonilo,aralquilcarbonilo,aralquenilo, alcoxialquilo, ariltioalquilo, ariloxialquilo, aralquiltioalquilo, aralcoxialquilo, alcoxiaralcoxialquilo,alcoxicarbonilalquilo, aminocarbonilo, aminocarbonilalquilo, alquilaminocarbonilo, N-arilaminocarbonilo, N-alquil-N-arilaminocarbonilo,alquilaminocarbonilalquilo, carboxialquilo, alquilamina, N-arilamina N-aralquilamina, N-alquil-N-aralquilamina, N-alquil-N-arilamina,This invention relates to the use of cyclooxygenase-2 inhibitors, or derivatives thereof, in the prevention and treatment of preterm labor. In particular, the invention describes a method for preventing and treating premature delivery in a subject, said method comprising treating the subject with a therapeutically effective amount of a compound of formula (I) where A is a 5 or 6 membered ring substituent selected. between unsaturated or partially unsaturated heterocyclic and carbocyclic rings, where R1 is at least one substituent selected from heterocycles, cycloalkyl, cycloalkenyl and aryl, where R1 is optionally substituted in a substitutable position, with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl , alkoxycarbonyl, hydroxy, hydroxyalkyl, haloalkoxy, amine, alkylamine, arylamine, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio, where R3 is selected from alkyl and amine and R3 is a radical selected from halo, alkyl, alkenyl, alkynyl, oxo , cyano, carboxyl, cyanoalkyl, heterocycloxy, alkyloxy, alkylthio, alkyl carbonyl, cycloalkyl aryl, haloalkyl, heterocyclo, cycloalkenyl, aralkyl, heterocycloalkyl, acyl alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonyl, alkylaminocarbonyl, N- arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamine, N-arylamine N-aralkylamine, N-alkyl-N-aralkylamine, N-alkyl-N-arylamine,

ARP980105483A 1997-10-31 1998-10-30 METHOD FOR USING CYCLOOXYGENASE-2 INHIBITORS IN THE MAINTENANCE OF FETAL DUCTUS ATERIOSUS DURING TREATMENT AND PREVENTION OF WORK PREMATURE WORK AR014000A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6388997P 1997-10-31 1997-10-31

Publications (1)

Publication Number Publication Date
AR014000A1 true AR014000A1 (en) 2001-01-31

Family

ID=22052179

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105483A AR014000A1 (en) 1997-10-31 1998-10-30 METHOD FOR USING CYCLOOXYGENASE-2 INHIBITORS IN THE MAINTENANCE OF FETAL DUCTUS ATERIOSUS DURING TREATMENT AND PREVENTION OF WORK PREMATURE WORK

Country Status (9)

Country Link
EP (1) EP1027048A2 (en)
JP (1) JP2001521889A (en)
AR (1) AR014000A1 (en)
AU (1) AU758566B2 (en)
BR (1) BR9813164A (en)
CA (1) CA2308639A1 (en)
TW (2) TW200404535A (en)
WO (1) WO1999022720A2 (en)
ZA (1) ZA989876B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1617716A (en) * 2000-06-08 2005-05-18 德克萨斯***大学评议会 Heterocycle derivatives and methods of use
EP1534305B9 (en) 2003-05-07 2007-03-07 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6718494A (en) * 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
EP0889724A1 (en) * 1996-02-27 1999-01-13 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Also Published As

Publication number Publication date
AU758566B2 (en) 2003-03-27
TW577739B (en) 2004-03-01
TW200404535A (en) 2004-04-01
ZA989876B (en) 1999-10-29
EP1027048A2 (en) 2000-08-16
WO1999022720A3 (en) 1999-08-26
CA2308639A1 (en) 1999-05-14
WO1999022720A2 (en) 1999-05-14
AU1192699A (en) 1999-05-24
JP2001521889A (en) 2001-11-13
BR9813164A (en) 2000-08-22

Similar Documents

Publication Publication Date Title
CU23116A3 (en) DERIVATIVES OF REPLACED BENCENSULFONAMIDE, AS COX-2 INHIBITORS
NZ509755A (en) Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia
PT772597E (en) 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION
PL322419A1 (en) Novel substituted compounds of biphenyl or phenylopyridine, method of obtaining them as well as pharmaceutic compositions containing such compounds
EA202090676A1 (en) METHODS OF ADMINISTRATION OF SOME VMAT2 INHIBITORS
MX2021015605A (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors.
BRPI0413848A (en) compound, process for preparing the compound, therapeutic composition for preventing inflammation and apoptosis, method for preventing inflammation and apoptosis, and use of caspase inhibiting compound or salt or stereoisomer thereof
HK1027474A1 (en) Phenyl heterocycles as cyclooxygenase-2 inhibitors
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
CY1107069T1 (en) USE OF COX-2 INHIBITORS AS IMMIGRANTS IN HIV / AIDS TREATMENT
DK0715623T3 (en) platelet aggregation inhibitors
AR014000A1 (en) METHOD FOR USING CYCLOOXYGENASE-2 INHIBITORS IN THE MAINTENANCE OF FETAL DUCTUS ATERIOSUS DURING TREATMENT AND PREVENTION OF WORK PREMATURE WORK
PT880504E (en) IMITAZOLES SUBSTITUTED BY HETEROCYLIC FOR THE TREATMENT OF INFLAMMATION
ES2110115T3 (en) PLATELET AGGREGATION INHIBITORS.
CR20210143A (en) Use of a cathepsin s inhibitor against the formation of anti-drug antibodies
HUP9901505A2 (en) Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men
AR038199A1 (en) COMBINED THERAPY FOR THE TREATMENT OF BACTERIAL INFECTIONS
BRPI0407039A (en) Use of a combination of an aromatase inhibitor, progestin and estrogen, pharmaceutical composition, and method of treatment of endometriosis.
FR3077201B1 (en) AMINO ACID DERIVATIVES CONTAINING A DISULFANYL GROUP IN THE FORM OF A NEP AND APN INHIBITOR FOR THE PREVENTION AND TREATMENT OF PAIN RELATING TO TWIN Nerve
PA8471901A1 (en) 2 "-DESOXY HYGROMYCIN DERIVATIVES
AR020306A1 (en) THERAPEUTIC COMPOSITION AND ITS USE AS AN INHIBITOR OF CICLOOXIGENASA-2 IN THE PREVENTION OF CARDIOVASCULAR ALTERATIONS.
AR035768A1 (en) COMPOUND DERIVED FROM BENCIMIDAZOL AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
AR012310A1 (en) COMPOSITION OF 4- [PIRAZOL-1-IL] -BENZENE-SULFONAMIDE INHIBITING CYCLOOXYGENASE-2 USEFUL IN THE TREATMENT AND PREVENTION OF DEMENTIA AND ITS PREPARATION TO PREPARE A MEDICATION TO TREAT THAT EVIL.
IT1307330B1 (en) New quinoline-4-carboxamide derivatives - are neurokinin-2 and -3 receptor antagonists which are useful for treating e.g. respiratory diseases, inflammatory diseases, allergies etc.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure